leisure time -WSS

leisure time

author：Wikipedia 2025-09-27 09:40:09 - browse：63973

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

To hear Sarepta CEO Doug Ingram tell it, the results Monday afternoon from a large trial of its gene therapy for Duchenne muscular dystrophy marked a clear medical breakthrough. “A massive win,” he told investors, that could lead to its approval for all patients with the fatal muscle-wasting disease regardless of age.

And yet the rest of the Duchenne community was more cautious in its enthusiasm. The study — the most rigorous test to date of a technology 30 years in the making — had technically failed, as so many had before it.

“It’s extremely frustrating,” said John Brandsema, a pediatric neurologist at Children’s Hospital of Philadelphia who worked on the study. “When you spend decades trying to bring therapies into the clinic for something so severe and just keep missing over and over again.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Meta looks to target Twitter with a rival app called Threads

WSS

Bright Health sells Medicare Advantage business to Molina

Trump demands the U.S. pay no more for drugs than other countries … again

Alkermes shareholders re

Hepatitis C has a cure — but many Americans still lack access to it

Activists slam private health insurers over coverage restrictions

Listen: PBM conflicts, RSV vaccines, & the future of flu season

focus

leisure time

knowledge

In age of alternative facts, a scholarly course on calling out crap

Medicare proposal to cover medical devices draws a mixed reaction

Hepatitis C has a cure — but many Americans still lack access to it

The cancer drug shortage isn’t new — and neither are the solutions

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Medical records are filled with copy

Medical leaders decry Supreme Court decision on affirmative action

7 people shot in DC, police say

BioMarin wins approval for gene therapy to treat hemophilia A

Medicare proposal to cover medical devices draws a mixed reaction

hotspot

Pfizer's Covid pill remains 89% effective in final analysis, company says

The cancer drug shortage isn’t new — and neither are the solutions

BioMarin wins approval for gene therapy to treat hemophilia A

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Wikipedia

entertainment

hotspot

focus